Fleischer, Michael
Lee, Inn
Erdlenbruch, Friedrich
Hinrichs, Lena
Petropoulos, Ioannis N.
Malik, Rayaz A.
Hartung, Hans-Peter
Kieseier, Bernd C.
Kleinschnitz, Christoph
Stettner, Mark
Funding for this research was provided by:
Universitätsklinikum Essen
Article History
Received: 7 August 2020
Accepted: 15 March 2021
First Online: 8 April 2021
Declarations
:
: Statement on ethics approval and consent was included. The name of the ethics committee that approved the study and the committee’s reference number was included.
: Not applicable
: Fleischer (none), Lee (none), Hinrichs (none), Petropoulos (none), Erdlenbruch (none), Malik served on the scientific advisory board and/or received speaker honoraria or travel funding from Biogen Idec, Merck, Pfizer, Novo Nordisk. Hartung received personal fees for consulting, serving on steering, and data monitoring committees from Bayer Healthcare, Biogen, Celgene Receptos, CSL Behring, GeNeuro, MedImmune, Merck, Novartis, Octapharma, Roche, Sanofi Genzyme, and Teva. Kieseier (none). Kleinschnitz (none), Stettner: served on the scientific advisory and/or received speaker honoraria or travel funding from UCB, Biogen Idec; Grifols, Genzyme, Roche, Merck, Novartis, Octapharma, CSL Behring, Sanofi-Aventis, TEVA, and Bayer.